Latest News and Press Releases

RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted Top-line results from the first...

RedHill has been granted the exclusive right to co-promote Mytesi® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved...

TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty...

TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

Last patient completed treatment for primary endpoint assessment in the Phase III study with RHB-104 for Crohn’s disease; Top-line results expected to be announced in approximately 3 months TEL-AVIV,...

Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 monthsTop-line results from confirmatory Phase III study with...

Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months Worldwide sales of Crohn’s disease therapies are estimated to...

Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2)RedHill expects to...

TEL-AVIV, Israel and RALEIGH, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...